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INTRODUCTION 
 
In  the  1960’s,  Hayflick  observed  that  human  cells 
displayed a finite lifespan when cultured in vitro[1]. He 
later determined that most cells had a maximal capacity 
to proliferate in vitro of about 50 population doublings 
(the Hayflick limit) after which they entered what he 
termed cellular senescence, a process characterized by 
irreversible  growth  arrest[2].  These  observations  led 
him  to  propose  a  cellular  theory  of  aging  whereby 
cellular senescence accounts for the aging process and 
on  the  contrary,  escape  from  senescence  leads  to 
cellular transformation and cancer. This theory is still 
widely  accepted  today  although  direct  proof  of  it  is 
lacking.  It  is  also  still  debated  whether  cellular 
senescence causes aging or conversely if aging causes 
cellular  senescence[3,4].  Nevertheless,  there  is  an 
increasing amount of experimental data demonstrating 
an accumulation of senescent cells in aged tissues[3,5]. 
 
Cellular  senescence  can  be  caused  by  intrinsic  or 
extrinsic  factors  and  this  distinction  is  important[6]. 
Intrinsic senescence is caused by telomere shortening, 
which occurs after each cell division. Cells that do not 
express  telomerase  thus  have  a  limited  number  of 
possible  cell  divisions  before  genomic  instability 
ensues. This triggers the p53, p21 and pRb pathways to 
promote growth arrest and cellular senescence. Because 
murine  cells  have  very  long  telomeres,  they  are  not 
believed  to  undergo  intrinsic  senescence  in  normal 
conditions.  Indeed,  mice  lacking  telomerase  activity 
only  show  signs  of  accelerated  aging  after  six 
generations[6].  However,  murine  cells  are  also 
renowned  for  their  high  rate  of  transformation  when 
cultured  in  vitro.  This  usually  occurs  after  very  few 
population doublings when the cells enter a crisis phase 
and stop proliferating. Although most of those cells do 
not survive, some transformed and immortalized clones 
often arise from the culture and display a high degree of 
genomic instability and a propensity for tumorigenesis. 
This  type  senescence  that  precedes  transformation  is 
thought  to  be  caused  by  artificial  laboratory  culture 
conditions (such as high oxygen) and is referred to as 
extrinsic  senescence.  It  mainly  involves  the  p16
INK4a 
pathway in human cells and also the p19/ARF pathway 
in  murine  cells.  In  human  cells,  both  intrinsic  and 
extrinsic senescence can thus coalesce to play a role in 
aging. 
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The process of aging is a systemic degenerative process 
caused  by  intrinsic  (genetic,  epigenetic)  and  extrinsic 
(environmental)  factors.  It  affects  multiple  organs, 
mainly  those  with  a  high  metabolic  demand  or  those 
which  are  mitotically  active  and  require  constant  or 
frequent regeneration[7]. As such, aging is associated 
with a decrease in the regenerative properties of many 
tissues  including  bone,  skin,  muscle,  brain  and  more. 
Adult  or  somatic  stem  cells  have  been  identified  in 
almost  every  organ  tested:  skin,  intestine,  bone  and 
bone marrow, liver, heart,  brain, pancreas, etc. These 
stem  cells  are  thought  to  sustain  tissue  growth, 
homeostasis  and  repair  throughout  the  lifetime  of  the 
organism.  In  consequence,  the  blunted  regenerative 
potential  of  tissues  observed  during  aging  may  be 
viewed as a stem cell disorder, where stem cells are lost 
or inactivated by senescence. 
 
Adult stem cells provide constant replacement cells for 
tissue  homeostasis  and  repair  while  at  the  same  time 
maintaining a pool of stem cells by the process of self-
renewal,  where  following  cell  division  at  least  one 
daughter  cell  is  still  a  stem  cell  whereas  the  other  is 
either  a  stem  cell  (symmetric  division)  or  a 
differentiated progeny (asymmetric division). The stem 
cell pool only regresses if a symmetric division giving 
rise to two differentiated progeny occurs, or if the stem 
cell undergoes cellular senescence (these two processes 
not  being  exclusive).  In  recent  years,  a  number  of 
studies have identified fibroblast growth factors (FGFs) 
and their receptors (FGFRs) as key regulators of both 
senescence  and  self-renewal  in  a  variety  of  stem  cell 
types.  
 
FGFs  (23  known  members)  and  FGFRs  (5  known 
members,  expressed  as  multiple  splice  variants)  have 
long been known for their important roles in embryonic 
development[8,9].  However,  the  vast  number  of 
somewhat  redundant  ligands  and  receptor  variants,  as 
well as the promiscuous ligand usage by the receptors 
has made it difficult to study the roles of FGFs/FGFRs 
using genetic methods[10]. Furthermore, FGF signaling 
is  modulated  by  tissue  specific  heparan-sulfate 
proteoglycans  (HSPGs)  that  either  inhibit  or  amplify 
FGFR  activation.  The  divergent  effects  of  FGF 
signaling  also  appear  to  depend  on  the  state  of 
differentiation of the cells, the repertoire of FGFRs they 
express,  and  the  presence  of  other  growth  factors  or 
cytokines.  Nevertheless,  as  further  tools  and  reagents 
are developed, a more comprehensive image is starting 
to emerge.  
 
The purpose of this Research Perspective article is to 
review the roles of FGFs and FGFRs in different stem 
cell populations and highlight their roles in stem cell 
self-renewal, cellular senescence and aging. 
 
FGF  SIGNALING  IN  EMBRYONIC 
DEVELOPMENT  AND  EMBRYONIC  STEM 
CELLS 
 
In early murine embryonic development FGF-4 is the 
first member to be expressed, from the 4 cell stage onto 
the blastocyst, egg cylinder and primitive streak[11]. Its 
deletion  causes  peri-implantation  embryonic  lethality 
(E4-5);  early  development  appears  normal  up  to  the 
Figure 1. Mechanisms of cellular senescence in human 
cells. In normal proliferating human cells, telomeres at the end 
of chromosomes are shortened at every cell division unless the 
cells  express  telomerase.  When  telomeres  get  too  short, 
genomic instability ensues and a DNA-damage response under 
the control of the p21 pathway is induced. This causes growth 
arrest and intrinsic cellular senescence. Transduction of  these 
senescence  cells  with  a  telomerase  construct  reverses  this 
growth arrest and leads to immortalization. When cells undergo 
stress  (e.g.  reactive  oxygen  species,  ionizing  radiations,  etc.) 
they  can  undergo  p16-mediated  extrinsic  senescence  even 
though  they  possess  long  telomeres.  Re-expression  of 
telomerase in this case does not rescue this irreversible growth 
arrest.  Murine  cells  have  very  long  telomeres  and  are  not 
thought  to  be  susceptible  to  intrinsic  senescence  in  normal 
conditions.  However,  they  are  very  sensitive  to  extrinsic 
senescence.  Murine  cells  often  escape  from  p16-mediated 
senescence and get immortalized but the mechanism for this is 
unclear. 
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blastocyst  stage  but  embryos  die  within  hours  after 
implantation  owing  to  deficient  inner  cell  mass 
formation  and  maintenance[12].  FGF-4  signaling 
appears to be important as early as the fifth cell division 
to  promote  cell  proliferation  onto  the  blastocyst 
stage[13]. FGF-4 probably signals through FGFR2 as  
this  receptor  is  the  first  detected  in  development, 
although early expression of FGFR1, 3 and 4 have also 
been inconsistently reported (probably owing to the few 
reliable antibodies available)[14,15]. Moreover, FGFR2 
deletion  recapitulates  FGF-4  deletion,  causing  early 
embryonic lethality (E6-8) due to defects in inner cell 
Figure  2.  Structure  and  signaling  downstream  of  FGFRs.  A)  FGFRs  possess  three  extracellular  immunoglobulin-like 
domains (Ig I to III), a transmembrane domain (TM) and an intracellular protein tyrosine kinase domain (PTK).The third Ig-like 
domain (III) is thought to confer ligand specificity. The C-terminal half of this IgIII domain (dotted line) is alternatively encoded by 
either exon 8 or 9 of the receptor gene, which create the two main isoforms of FGFR1, 2 and 3 (IIIb for exon 8 and IIIc for exon 9). 
Other isoforms also exist (no PTK domain, no TM domain) but are less abundant. B) Creation of the ternary complex between 
heparan sulfate proteoglycans (HSPGs), FGF ligands, and FGFRs leads to autophosphorylation of the PTK domains and activation 
of a number of intracellular pathways downstream. FRS2 and Grb2 and the main mediators of the signaling and activate various 
effectors such as PI3K/AKT and MAPKs. Other pathways (Shp2, PLC-γ) are also activated. Note that activation of the PI3K 
pathway  can  lead  to  phosphorylation  of  MDM2  on  Ser186,  leading  to  its  translocation  to  the  nucleus  and  subsequent 
degradation of p53. 
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mass.  FGFR1  deletion  is  also  lethal  (E7.5-9.5)  and 
appears  to  cause  defects  in  gastrulation,  mainly  by 
affecting axial patterning and migration/proliferation of 
cells  through  the  primitive  streak,  thus  inhibiting 
mesoderm and endoderm specification[16,17]. FGFR3 
deletion on the other hand is not embryonic lethal but 
mice  display  skeletal  malformations  that  may  lead  to 
premature death (see section on skeletal/mesenchymal 
stem cells below), whereas FGFR4 null mice show no 
obvious phenotype. The functions of this latter receptor 
in development and postnatal life remain unclear as well 
as that of FGFR5. 
 
Murine embryonic stem cells (mESCs) have historically 
been  derived  from  the  inner  cell  mass  of  the 
blastocyst[18,19] or the epiblast (although these ESCs 
are considered more primed for gastrulation and germ 
layer  commitment).  Since  FGF-4
-/-  embryos  fail  to 
develop  because  of  defects  in  inner  cell  mass 
proliferation and germ layers specification, it has been 
assumed that FGF signaling in mESCs was required for 
their  differentiation  or  lineage  commitment.  Of  note, 
mESCs constitutively express FGF-4 which is thought 
to act in an autocrine manner. Undifferentiated mESCs 
were  found  to  express  high  levels  of  FGFR1  and  4 
which are maintained during differentiation[15]. They 
also  express  FGFR2(IIIb)  and  FGFR3(IIIc)  but 
upregulate  FGFR2(IIIc)  and  FGFR3(IIIb)  upon 
differentiation. FGF-4
-/- mESCs do not display defects 
in proliferation in vitro and are capable of multilineage 
differentiation,  however  the  survival  of  those 
differentiated  progeny  is  severely  compromised, 
although the underlying mechanism for this phenotype 
is  still  unclear[20].  Further  studies  using  FGF-4
-/- 
mESCs  or  specific  inhibitors  of  FGFR1  and  3 
confirmed  that  inhibition  of  FGF  signaling  through 
these  receptors  could  maintain  mESCs  in  a  self-
renewing,  pluripotent  state[21,22].  However,  these 
studies also suggest that FGFR1/3 signaling, as well as 
the  presence  of  specific  HSPGs,  may  act  more  as  a 
priming or permissive signal for  differentiation rather 
than a differentiation cue itself. Taken together, these 
studies  suggest  that  FGF  signaling  in  murine 
embryogenesis  and  ESCs  may  have  stage  specific 
effects.  FGF-4  signaling  through  FGFR2  stimulates 
ESCs  proliferation  from  the  fifth  division  to  the 
establishment of the inner cell mass in the blastocyst, 
whereas  signaling  through  FGFR1/3  in  peri-
implantation  embryos  and  epiblast  ESCs  is  important 
for germ layer specification. However, the exact timing 
of expression of the various receptor isoforms in early 
lineage  specification  and  their  role  in  self-renewal, 
priming and differentiation of mESCs remains unclear 
to date. 
 
The  study  of  molecular  events  in  human  post-
implantation  embryogenesis  is  complicated  by  ethical 
and technical limitations. It is however possible to study 
pre-implantation  embryos  from  which  are  derived 
humans ESCs. It must be noted that hESCs might be 
more  related  to  epiblast-derived  (primed)  mESCs  in 
terms  of  properties  and  functionality.  Nevertheless, 
hESCs have been found to express several molecular-
mass isoforms of FGF-2, 11 and 13 (but not FGF-4) as 
well  as  the  whole  repertoire  of  FGFRs  with  the 
following relative abundance (mRNA levels): FGFR1 > 
FGFR3  >  FGFR4  >  FGFR2  [23].  These  levels  are 
modulated  during  hESCs  differentiation,  showing  an 
initial  decrease  followed  by  upregulation  in  more 
advanced differentiation. Early evidence suggested that 
FGF signaling might be important for proliferation and 
self-renewal  of  hESCs  in  vitro[24-27].  These 
observations  were  confirmed  by  many  groups  and  to 
date FGF-2 is a necessary supplement to hMSCs culture 
medium, independently of the presence or absence of a 
feeder  layer.  The  maintenance  of  pluripotency  (self-
renewal) by FGF-2 on hESCs may be in part attributed 
to modulation of Wnt signaling through PI3K [28], but 
a  recent  study  again  suggests  that  its  effects  may  be 
stage  specific  or  dependent  on  context[29].  Indeed, 
FGF-2  may  also  be  important  to  sustain  Nanog 
expression  during  BMP-4  induced  differentiation  of 
hESCs and promote mesendoderm over trophoectoderm 
differentiation. 
 
In summary, the roles of FGF signaling in murine and 
human  embryogenesis  are  diverse  and  appear  stage 
specific. They are probably modulated by the context 
(presence and type of HSPGs), the differentiation status 
of target cells, and the repertoire of FGFRs these cells 
express. However, FGF signaling is important for self-
renewal  and  proliferation  of  primitive  ESCs  and  for 
migration,  proliferation  and  lineage  commitment  of 
more differentiated cells. 
 
FGF SIGNALING IN MESODERMAL STEM 
CELLS AND TISSUES 
 
“Fibroblast  growth  factor”  was  first  isolated  in  1974 
from  bovine  pituitary  gland  and  shown  to  have  a 
mitogenic  effect  on  many  cells  types[30].  The 
prototypical FGF ligands, acidic FGF (aFGF or FGF-1) 
and basic FGF (bFGF or FGF-2), were then purified by 
heparin affinity chromatography in the early 1980’s as 
   
www.impactaging.com                  923                                      AGING, October 2011, Vol.3 No.10  
the first potent endothelial cells mitogens[31-33]. Latter 
observations  showed  that  FGF  signaling  inhibition 
impairs mesodermal patterning and bone formation, and 
that mutations in FGFRs cause skeletal abnormalities in 
mice  and  humans.  It  is  thus  not  surprising  that  the 
FGFs/FGFRs  systems  have  been  mostly  studied  in 
mesodermal  and  mesenchymal  tissues  to  date.  This 
section will review the roles of FGF signaling in three 
mesoderm-derived  tissues  and  their  associated  stem 
cells: skeletal tissue, vascular tissue and hematopoietic 
tissue. 
 
Mesenchymal stem cells and skeletal tissues 
 
The importance of FGF signaling in skeletal tissues was 
first  highlighted  by  genetic  linkage  analysis 
demonstrating  that  the  etiology  of  achondrodysplasia 
(one  of  the  most  common  forms  of  dwarfism  in 
humans)  was  due  to  activating  point  mutations  in 
FGFR3[34,35]. Other forms of skeletal dysplasias were 
then linked to FGFR1 and 2 mutations. Broadly, these 
conditions  can  be  divided  in  two  categories: 
achondrodysplasias  and  craniosynostosis  syndromes. 
Some  particularly  severe  achondrodysplasias  are 
postnatally lethal within a few months. They are usually 
caused  by  activating  mutations  in  FGFR3,  which 
suggests  that  this  receptor  is  a  negative  regulator  of 
chondrogenesis.  The  craniosynostosis  syndromes  are 
characterized  by  premature  cranial  sutures  fusion  but 
are  also  associated  with  appendicular  skeletal 
malformations and mental retardation. Most of them are 
associated with activating or gain-of-function mutation 
in  FGFR2  but  others  link  to  FGFR1  and  3.  These 
mutations  lead  to  increased  osteoblast  differentiation 
and maturation, implying a role for these receptors as 
positive regulators of osteogenesis.  
 
In the early stages of bone development, FGFR1(IIIc) is 
expressed in limb mesenchyme whereas FGFR2(IIIb) is 
expressed in overlying ectoderm[36]. There appears to 
be  an  intimate  crosstalk  between  these  tissues  as 
mesenchyme-derived  FGF-10  signals  through 
ectodermal FGFR2b to initiate apical ectodermal ridge 
(AER) formation and induces FGF8 expression, which 
in  turn  activates  mesenchymal  FGFR1c.    At  the 
condensation stage, FGFR1 continues to be expressed in 
loose  mesenchyme  and  in  the  condensation  whereas 
FGFR2 is expressed solely in the condensation[37]. At 
later  stages  of  development,  FGFR1  and  2  are  still 
expressed in perichondrium and periosteum and FGFR1 
can also be observed in osteogenic lineage cells within 
the marrow cavity, endosteum and trabecular bone[34]. 
FGFR3  is  expressed  by  proliferating  chondrocytes  at 
the  onset  of  chondrogenesis  and  is  maintained  until 
growth  plate  closure.  When  chondrocytes  stop 
proliferating  to  become  prehypertrophic,  they  down 
regulate  FGFR3  and  upregulate  FGFR1. 
Perichondrium-derived  FGF18  appears  to  activate 
FGFR3  on  proliferating  chondrocyte  to  limit  their 
proliferation[38-40]. 
 
Because FGFR1 and 2 knockout murine embryos die 
before  skeletal  development,  conditional  knockout 
techniques have been used to elucidate the roles of these 
receptors  in  bone  lineage  cells.  FGFR1  signaling  in 
osteogenic cells appears to have developmental stage-
specific  effects.  When  inactivated  at  the  early 
condensation  phase  in  brachyury  expressing  cells,  a 
decreased proliferation of mesenchymal progenitors is 
observed, along with decreased condensation sizes and 
numbers  and  delayed  patterning  (segmentation, 
branching)[41].  When  inactivated  in  collagen  2 
expressing  osteo-chondro-progenitors,  osteoblasts 
showed  delayed  maturation  based  on  collagen  1  and 
osteopontin expression, but normal commitment to the 
osteoblast  lineage  based  on  Runx2  mRNA 
expression[42]. When FGFR1 is inactivated in mature, 
collagen  1  expressing  osteoblasts,  the  resulting 
phenotype  suggest  an  accelerated  differentiation 
resulting  in  increased  trabecular  volume  and 
mineralization[42]. FGFR1 thus seems to be required at 
different  stages  of  bone  cell  development:  1)  it 
stimulates  limb  bud  elongation  in  the  proximal-distal 
axis;  2)  it  increases  mesenchymal  progenitors 
proliferation  and  survival;  3)  it  is  involved  in  the 
patterning of the skeletal elements; 4) it is required for 
commitment of the progenitors to the osteoblast lineage; 
and 5) it inhibits terminal differentiation of osteoblasts. 
 
A similar strategy has been used to study the role of 
FGFR2 in bone lineage cells. Conditional inactivation 
of  this  receptor  in  Dermo1  (Twist2,  expressed  in  the 
mesenchymal  condensation  giving  rise  to  both 
osteoblasts and chondrocytes) expressing cells resulted 
in  severe  dwarfism  accompanied  by  reduced  bone 
mineral  density[43].  At  E16.5,  normal  levels  and 
distribution  of  Runx2,  osteopontin,  collagen  1  and 
osteocalcin were observed but were drastically reduced 
in postnatal animals, reflecting a decreased osteoblast 
number. Significantly less trabecular bone was formed 
in  conditional  knockout  animals  and  trabecular 
osteoblasts  appeared  atrophic  and  disorganized. 
Perichondrium and periosteum also showed decreased 
thickness, with reduced osteoblasts number and mineral 
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apposition  rate.  Osteoblasts  and  progenitors 
proliferation was reduced in perichondrium, trabecular 
bone  and  cortical  bone.  In  another  study,  the 
mesenchymal isoform (IIIc) of FGFR2 was disrupted by 
inserting  a  stop  codon  in  exon  9  of  the  FGFR2 
gene[44].  These  mice  also  exhibit  dwarfism  with 
skeletal defects in both cranial and long bones. These 
mice  have  a  delayed  onset  of  mineralization,  early 
synostosis caused by a loss of proliferating osteoblasts, 
deficient growth of the skull base and a narrowing of 
the hypertrophic chondrocyte layer in the growth plate 
of  long  bones.  The  different  phenotypes  observed  in 
these two mouse models could be explained by possible 
alternative  exon  usage  in  the  latter,  although  the 
expression of FGFR2(IIIb) was reported normal at least 
between  E12.5  and  E14.5.  Nevertheless,  we  can 
conclude from these studies that FGFR2 is an important 
regulator  of  osteoprogenitors  proliferation  and  of  the 
anabolic function of mature osteoblasts. 
 
The role of FGF signaling in skeletal cells has also been 
studied  in  vitro  in  mesenchymal  stem  cells  (skeletal 
stem cells), which are thought to give rise to all skeletal 
or  mesenchymal  cells  in  bones  and  sustain  bone 
homeostasis and repair throughout life. The mitogenic 
effect of FGF on mesenchymal stem cells (MSCs) was 
first  described  over  20  years  ago[45].  Several 
subsequent studies have confirmed this observation and 
showed  that  FGF  signaling  maintains  MSCs  in  an 
undifferentiated  state  during  proliferation  while 
preserving  their  multipotentiality[46-53].  In  other 
words,  FGF  appears  to  promote  self-renewal  and 
maintain  stemness  of  MSCs  in  vitro.  However,  the 
molecular mechanisms underlying this effect have only 
recently been investigated in more details. Mansukhani 
et al. (2005) provided evidence that signaling through 
FGFR2  inhibits  osteoblast  differentiation  by  inducing 
the expression of the pluripotency marker Sox2, which 
antagonizes Wnt signaling (a postitive regulator of bone 
formation) by binding to and inhibiting β-catenin[54]. 
The  same  group  later  demonstrated  that  Sox2  was 
required for self-renewal of osteogenic cells[55]. On the 
other hand, FGF signaling has also been described as a 
negative regulator of MSCs senescence in both human 
and mouse[56-59].  More specifically, we have shown 
that  MSCs  express  both  FGFR1  and  2  and  that  FGF 
stimulation  is  absolutely  required  to  avoid  extrinsic 
senescence  of  murine  MSCs[58].  FGFR  signaling  in 
MSCs induces phosphorylation of MDM2 on serine 186 
in  a  PI3K/AKT-dependent  manner.  This  post-
translational  modification  releases  MDM2  from  its 
inhibitor p19/ARF, induces its nuclear translocation and 
enhances  its  ubiquitin-ligase  activity  as  well  as  its 
affinity  for  p53,  targeting  the  latter  for  proteosomal 
degration[60,61]. 
 
The observations that FGF acts as a mitogen (probably 
by ERK1/2 activation), a multipotency factor (through 
Sox2 induction) and an inhibitor of cellular senescence 
(through a PI3K-AKT-MDM2 pathway) are significant 
in  that  they  may  explain  how  MSCs  are  capable  of 
maintaining a sufficient pool of progenitors during bone 
development,  growth,  homeostasis  and  repair  for  the 
lifespan  of  the  organism.  These  observations  also 
provide  potential  therapeutic  targets  as  senescence  of 
osteoblasts and their progenitors is an important cause 
of age-associated bone loss and osteoporosis[62]. Data 
from  both  conditional  knockout  experiments  and  in 
vitro  experiments  using  MSCs  suggest  that  FGF 
signaling may act as a balancing factor to maintain the 
size  of  the  skeletal  progenitor  pool  while  avoiding 
overgrowth, by stimulating stem cell proliferation while 
inducing committed progenitor differentiation. 
 
Endothelial progenitor cells and vasculature 
 
In  embryonic  development,  mesodermal  cells  arising 
from  the  posterior  primitive  streak  are  thought  to 
migrate  to  the  yolk  sac  and  to  the  para-aortic 
splanchnopleura  (precursor  to  the  aorta-gonad-
mesonephros,  AGM)  and  differentiate  into 
haemangioblasts,  common  progenitors  of  both 
endothelial and hematopoietic cells[63,64]. As already 
mentioned, FGF-2 was the first potent angiogenic factor 
identified in the early 1980’s, which appears to signal 
exclusively through FGFR1 in endothelial cells (ECs). 
However,  the  specific  role  of  FGF  signaling  in  ECs 
remains elusive. It has proven difficult to study, largely 
because:  1)  FGFR1  knockout  mice  die  shortly  after 
gastrulation and before the onset of vascularisation, 2) 
ECs  are  highly  heterogeneous  in  terms  of  markers 
expression  and  phenotype,  precluding  the  use  of 
conditional  knockout  techniques,  3)  various  non-
equivalent  sources  of  ECs  are  used  for  in  vitro 
experiments, and 4) quite paradoxically very few ECs 
express  FGF  receptors  in  vivo,  with  expression 
restricted mainly to large vessels and within less than 
20%  of  the  cells  (however  ex  vivo  cultured  ECs  do 
express  high  levels  of  FGFR1)[65,66].  Thus,  FGFR1 
expression  by  ECs  has  been  largely  assumed  to  be 
restricted  to  proliferating  cells  but  the  physiological 
significance  and  causality  between  proliferation  and 
receptor expression remains debatable and may reflect 
an indirect effect. 
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The first evidence that the mitogenic effect of FGF-2 on 
ECs may be indirect was provided when it was shown 
that FGF-2 upregulated VEGF expression and blocking 
of VEGF using antibodies completely abolished FGF-2-
induced ECs proliferation in vitro and angiogenesis in 
vivo[67]. Using embryoid bodies derived from FGFR1
-/- 
ES  cells,  which  under  appropriate  conditions 
recapitulate  haemangioblasts  differentiation  in  vitro, 
Magnusson et al. (2005,2007) demonstrated that FGFR1 
was  indeed  not  necessary  for  ECs  differentiation  and 
vascular plexus formation, it was however required for 
hematopoietic  development[68,69].  Moreover,  the 
FGFR
-/- embryoid bodies contained more blood vessels 
and  ECs  derived  from  them  proliferated  faster.  In  a 
more recent study, Murakami et al. (2008) used soluble 
FGFRs in vivo to demonstrate the importance of FGF 
signaling  in  maintaining  vascular  integrity,  more 
specifically in maintaining adherens and tight junctions 
between ECs[70]. However because FGFRs are poorly 
expressed  by  ECs  in  vivo,  it  is  not  clear  whether 
blocking FGF signaling affected ECs directly or rather 
the  underlying  pericytes  and  vascular  smooth  muscle 
cells. The same group recently demonstrated that one of 
the effects of FGF stimulation on ECs was actually to 
modulate  their  responsiveness  to  VEGF,  in  part  by 
upregulation of VEGFR2[71]. These and other studies 
(reviewed in [72]) indicate that one of the major roles of 
FGF signaling in ECs might be to orchestrate a complex 
crosstalk  between  ECs  and  pericytes  by  not  only 
modulating  the  production  of  other  growth  factors 
(amongst which PDGF and VEGF appear pivotal) but 
also  the  responsiveness  of  the  cells  to  these  factors. 
Quite  interestingly,  FGF  also  appears  to  inhibit 
senescence  in ECs.  Indeed,  senescent  HUVECs  loose 
responsiveness to FGF stimulation[73] whereas primary 
ECs and HUVECs upregulate telomerase in response to 
FGF-2 but not VEGF[74]. Moreover, HUVECs cultured 
without growth factors of with VEGF alone have been 
shown  to  enter  senescence  within  15  population 
doublings whereas the single addition of FGF-2 allowed 
the  cells  to  proliferate  up  to  40 population  doublings 
before onset of senescence[75]. 
 
From  what  has  just  been  described  and  contrary  to 
widespread belief, it is obvious that FGFs are not mere 
mitogens for ECs and in fact they may even exert their 
effects mostly by indirect means, whether by acting on 
accessory cells such as pericytes or by modulating the 
activity of other growth factors. This is supported by the 
low FGFR1 expression by ECs in vivo and the fact that 
FGFR
-/-  embryoid  bodies  show  no  obvious  defects  in 
angiogenesis. It could be that FGF signaling serves to 
protect  ECs  from  cellular  senescence  during  active 
proliferation  or  that  FGFR1  is  only  expressed  in 
endothelial  progenitors,  but  this  requires  more 
investigations. A fundamental requirement that needs to 
be  addressed  before  answering  some  of  these 
unresolved  questions  is  a  better  understanding  of  the 
heterogeneity  of  ECs  in  vivo  and  in  vitro,  of  their 
phenotypic differences and various physiological roles. 
As not all ECs are the equivalent, this would enable to 
test the effects of FGF stimulation on specific subsets of 
ECs. 
 
Hematopoietic stem cells and blood cells 
 
As already mentioned, hematopoietic stem cells (HSCs) 
arise  from  haemangioblasts  located  in  the  AGM  and 
yolk  sac  during  embryonic  development,  before 
undergoing a journey that will take them to the placenta 
and fetal liver and eventually the bone marrow shortly 
before birth[64]. In this latter location, they will self-
renew and give rise to the billions of new blood cells 
required  per  day,  for  the  lifespan  of  the  organism. 
Although  the  importance  of  FGF  signaling  in 
hematopoiesis as long been recognized and studied, its 
specific  role  in  HSC  self-renewal,  proliferation  and 
lineage  commitment  remains  controversial  to  this 
day[76,77].  
 
FGF-2  was  initially  shown  to  be  a  mitogen  for 
multipotent  progenitors  from  bone  marrow,  mostly  in 
the  myeloid  lineage[78-80].  Although  ineffective  by 
itself, it was thought to potentiate the effects of other 
growth  factors  and  thus  act  as  a  permissive  factor. 
Indeed, it appears to synergize with IL3, GM-CSF and 
EPO  to  increase  the  production  of  CFU-GEMM  and 
with SCF and GM-CSF to stimulate myelopoiesis[81]. 
FGFR1  and  2  were  also  found  on  most  blood  cells, 
including  megakaryocytes,  platelets,  macrophages, 
granulocytes  and  to  a  lesser  extent  on  B  and  T 
lymphocytes. The indirect effect of FGF stimulation on 
blood cell proliferation was supported by the fact that 
FGF-1  and  2  stimulated  the  proliferation  of 
megakaryocytes  and  erythroleukemia  cells  but  this 
effect  was  blocked  by  anti-IL6  antibodies[82].  The 
stimulatory  effect  of  FGF  on  megakaryopoiesis 
nevertheless appears very potent since daily injections 
of recombinant FGF-4 or FGF-4 adenovirus completely 
rescues thrompocytopenia in TPO deficient mice[83]. In 
this model, FGF-4 increased megakaryocytes adhesion 
to blood vessels and their subsequent maturation.  
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While the mitogenic effect of FGF on myeloid cells is 
obvious,  its  effect  on  embryonic  and  adult  HSCs  is 
more  controversial.  Berardi  and  colleagues(1995)[84] 
found no stimulatory effect of FGF on human CD34+ 
cells  from  bone  marrow,  whereas  Wagner  et  al. 
(2011)[85] observed a greater proliferation and NOD-
SCID reconstitution of CD34+ cell derived from human 
cord blood when expanded on mesenchymal stem cells 
with TPO, SCF and FGF1. Obviously, in the latter study 
we cannot exclude an indirect effect of FGF through the 
feeder layer as FGFRs expression in the two cell types 
was  not  tested.  More  recently,  it  was  shown  that  a 
combination of SCF, TPO, FGF1, IGFBP2 and Angptl5 
was  necessary  to  expand  serially  transplantable 
CD34+CD133+ cells from cord blood[86,87].  
 
In mice, it was first shown that FGF-2 signaling through 
FGFR1 was required for hematopoietic commitment of 
haemangioblasts derived from ESCs[69,88]. Moreover, 
Miller  et  al.  (2003)  showed  that  all  long-term 
repopulating cells were found in the c-kit+/Sca-1+/Lin- 
(KSL) FGFR1+ fraction of bone marrow cells, although 
only 0.2% of these were of hematopoietic origin[89]. 
These  cells  expressed  FGFR1,  3  and  4  and  could  be 
expanded for 4 weeks in vitro in the presence of FGF1 
while maintaining their multipotentiality in vitro and in 
vivo,  although  this  was  not  tested  in  single-cell 
transplantations. In another study, a constitutively active 
FGFR2 was expressed in hematopoietic cells under the 
Tie2  promoter.  These  mice  showed  no  obvious 
hematopoietic  defects  but  their  KSL  cells  possessed 
increased  multilineage  reconstitution  and  decreased 
apoptosis  after  transplantation  into  wild-type 
animals[90].  On  the  other  hand,  FGF-4  and  8  were 
found  to  inhibit  blood  formation  in  chick  embryos 
whereas  inhibition  of  FGF  signaling  induced  ectopic 
blood  island  formation[91].  Furthermore,  FGF 
stimulation has been shown to suppress the expansion 
of activated HOXB4-overexpressing HSCs derived for 
ESCs or adult marrow[92]. In this same study however, 
FGF was found to stimulate the proliferation of normal 
HSCs not overexpressing HOXB4.  
 
The  wide  variety  of  cell  types  used,  purity  of  cell 
populations, culture conditions and endpoint assays to 
determine the stemness of HSCs in the studies described 
here probably explain the controversy regarding the role 
of  FGF  in  hematopoiesis.  As  our  definition  of  HSCs 
constantly evolves and better techniques are available to 
study these cells at near purity[93],  it  will clearly be 
necessary to revisit the role of FGF signaling in better 
defined populations using gold standard assays such as 
single-cell  assays  and  transplants.  Despite  apparently 
contradictory results however, it is probably safe to say 
that as in other tissues, FGF could have stage-specific 
effects,  with  stimulation  of  self-renewal  in  stem  cells 
and early progenitors and pro-differentiation effects on 
later progenitors. Although to our knowledge there has 
been  no  published  studies  linking  FGF  signaling  and 
senescence of HSCs, it is intriguing that MDM2 (which 
we  have  found  to  mediate  FGF-induced  inhibition  of 
senescence in MSCs)[58] was found to be required for 
HSCs  survival  following  their  colonization  of  bone 
marrow[94]. Indeed, MDM2 knockout mice expressing 
a  hypomorphic  p53  allele  to  rescue  their  embryonic 
lethal  phenotype  die  shortly  after  birth  from  marrow 
failure,  showing  extensive  medullary  senescence  and 
hypocellularity. Since MDM2 is a negative regulator of 
p53 and may thus improve HSCs self-renewal[95], and 
because  senescence  leads  to  decreased  HSC  function 
with  aging[96,97],  it  would  be  interesting  and 
potentially of  therapeutic use to see if  FGF signaling 
also directly modulates MDM2 activity in HSCs. 
 
FGF SIGNALING IN ECTODERMAL STEM 
CELLS AND TISSUES 
 
The  importance  of  FGF  signaling  in  central  and 
peripheral nervous system both during development and 
postnatal life has been long recognized. In addition to 
the  difficulties  in  studying  FGF  signaling  mentioned 
above  for  other  tissues,  our  knowledge  of  brain 
development and neural stem cells has greatly evolved 
in the last two decades rendering previous conclusions 
obsolete or in any case requiring re-evaluation. The skin 
is  another  ectoderm-derived  tissue  containing  various 
stem cell populations where FGFs and their receptors 
are widely distributed, yet very little is known about the 
precise  role  of  FGF  signaling  in  skin  homeostasis  or 
repair and it will not be discussed here. This section will 
review what  is known about  FGF signaling in neural 
tissue. 
 
Neural stem cells and the nervous system 
 
During  embryonic  development,  the  nervous  system 
arises  shortly  after  gastrulation  from  neuroepithelium 
located  along  the  dorsal  midline  of  the  embryo  (the 
prospective neural plate) and then folds into the neural 
tube  before  undergoing  various  patterning  events  and 
specification.    Whereas  most  neural  cells  in  early 
embryonic development are multipotent (they can give 
rise to both neurons and glia), neural stem cells (NSCs) 
become restricted to specific areas later in development 
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and postnatal life: the cerebellum, the subgranular zone 
(SGZ)  of  the  dentate  gyrus  in  the  hippocampus,  and 
subependymal  zone  (SEZ,  subventricular  zone  [SVZ] 
during development) lining the lateral ventricles[98,99]. 
NSCs  in  the  cerebellum  are  only  present  for  a  few 
weeks in postnatal animals whereas NSCs in the SGZ 
produce  excitatory  granule  neurons  for  their  entire 
lifespan. NSCs in the SVZ are thought to give rise to 
most  central  nervous  system  neurons  and  glia  in  the 
developing mouse telencephalon and continue lifelong 
to  provide  neural  progenitors  that  migrate  along  the 
rostral migratory stream to the olfactory bulb, a major 
zone  of  adult  neurogenesis[100].  These  cells  have  a 
radial glia identity during development and throughout 
neurogenesis, after which they adopt an astroglial stem 
cell  (the  adult  NSCs  in  the  SEZ)  or  ependymal 
phenotype.  This  glial  identity  of  NSCs  is  significant 
since it implies that other adult glia such as NG2 glia or 
even  astrocytes,  may  under  certain  circumstances  de-
differentiate  to  a  more  primitive  multipotent  state  to 
participate in tissue repair, although this remains to be 
proven in vivo[101]. 
 
FGF  signaling  has  long  been  acknowledged  for  its 
neural  induction  role  in  the  developing 
embryo[102,103]  as  well  as  for  its  mitogenic/self-
renewal effect on NSCs in vitro and in vivo[104-106]. 
Indeed, FGF-2 in combination with EGF is ubiquitously 
used to expand NSCs in the neurosphere assay. At least 
10  of  the  23  FGF  ligands  have  been described  to  be 
expressed in the brain. FGFR1 is expressed as early as 
E8.5-9.5  in  mouse  telencephalon  and  persists  in  the 
ventricular  zone  and  dentate  gyrus  later  on[107,108]. 
Expression  of  FGFR2  and  3  have  also  been  reported 
and seem to be highly expressed by glial cells, mostly in 
the  SEZ  and  SGZ  but  also  around  brain  lesions 
following trauma[105,109]. The expression of FGFRs 
and their ligands appears very dynamic and may have 
stage  specific  effects  during  development  and  adult 
life[110-112].  Interestingly,  FGF-2  and  HSPGs  have 
been found closely associated with proliferating NSCs 
in  vivo  and  may  also  regulate  NSCs  self-renewal  in 
vitro[106,113].  Moreover,  radial  glia  in  zebrafish 
appear to have increased FGF signaling[114].  
 
Aging is usually associated with a decline in cognitive 
functions  including  memory  as  well  as  decreased 
regenerative capacity. Aging has also been associated 
with decreased NSCs or progenitors number and self-
renewal capacity in the SEZ (see [115] and references 
therein),  which  may  correspond  to  increased  NSC 
senescence in vivo[116,117]. The number of FGFR2+ 
glial cells is also decreased in the olfactory bulb, SEZ, 
cerebellum  and  hippocampus  of  aged  mice[109]. 
Interestingly,  administration  of  FGF-2  either 
intraventricular  or  subcutaneous  appears  to  increase 
neurogenesis  and  NSCs  proliferation  in  the  SEZ  and 
SGZ  of  both  young  and  aged  mice  [118,119]. 
Furthermore,  FGF  has  been  shown  to  protect  against 
memory impairment in senescence-accelerated mice, a 
murine model of aging[120,121]. It might be relevant to 
point out that at least one strain of senescent-accelerated 
mice  with  an  increased  neurological  senescent 
phenotype resembling human aging has been shown to 
have a 50% deletion of its FGF-1 gene, leading to the 
complete absence of the protein in the brain. 
 
From the studies presented here, it is obvious that FGF 
signaling  plays  a  major  role  in  regulating  NSCs 
proliferation  and  self-renewal  in  vitro  and  in  vivo. 
There is also ample evidence that it may have a pro-
differentiation  effect  on  more  committed  progenitors. 
As our understanding of NSCs and brain development 
increases, it will be possible to specify these roles more 
precisely by using conditional knockout techniques. The 
strong  association  between  FGF  signaling  and  NSCs 
senescence and aging should serve as an incentive for 
these  future  studies  in  the  hope  of  developing  new 
treatments  against  neurological  degeneration  and 
possibly brain repair after trauma. 
 
CONCLUDING REMARKS 
 
Throughout this review, we have seen that FGFs and 
their  receptors  play  important  roles  in  the  embryonic 
development,  homeostasis  and  repair  of  most  organs. 
The effects of FGF signaling can be in part attributed to 
the stimulation of self-renewal in endogenous somatic 
stem cells within these organs, but there is also much 
evidence  that  FGF  signaling  also  plays  a  role  in  the 
concomitant  inhibition  of  cellular  senescence  in  stem 
cells. The evidence presented here also suggests a role 
of  FGF  signaling  in  the  more  committed  cells 
downstream  of  stem  cells,  a  role  that  appears  to 
stimulate differentiation. Moreover, in most cell types 
studied, FGF seems to play a permissive role rather than 
a  direct  inductive  or  instructional  role,  usually  by 
modifying  the  responsiveness  of  the  cells  to  other 
factors  or  by  potentiating  and  synergizing  with  other 
signals. That seems to hold true in both stem cell self-
renewal  and  differentiation  of  more  committed  cells. 
Although not discussed here FGF signaling also plays a 
major  role  in  endodermal  tissues,  in  lung  patterning, 
liver and pancreas specification, and in self-renewal of 
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stem cells in the intestinal crypts for instance. However, 
these  tissues  have  not  received  as  much  attention  in 
publications and little is yet known about the roles of 
FGF  signaling  in  their  maintenance  into  adulthood. 
Nevertheless,  the  roles  we  have  described  for  FGF 
signaling  in  regulation  of  stem  cells  self-renewal  and 
aging, the fact that our definitions and understanding of 
these same stem cells is better refined every day, and 
the  development  of  more  advanced  reagents  and 
techniques  to  study  stem  cells  should  stimulate  more 
research into this field.  
 
The roles played by FGFs and FGFRs in aging or age-
related disorders are gradually being unveiled. This is 
exemplified by the accelerated aging-like phenotype of 
FGF-23  knockout  mice[122]  and  by  the  decreased 
expression  of  FGF  ligands  and  receptors  (or  at  least 
blunted  responsiveness  to  FGF  signaling)  in  aged 
tissues  such  as  brain,  bone  and  skin[123-127].  Since 
FGF signaling is so potent at inducing stem cell self-
renewal  and  inhibiting  their  senescence,  therapeutic 
targeting of FGF signaling components by recombinant 
proteins, gene therapy or small molecules could well be 
used to reverse some of the effects of aging. In fact, 
various FGFs are currently being tested therapeutically 
for  a  number  of  age-related  disorders  such  as 
cardiovascular diseases, diabetes, osteoarthritis, chronic 
kidney disease, Parkinson’s disease and mood disorders 
(reviewed  in[128],  also  see  http://clinicaltrials.gov). 
Most  of  the  stem  cell  populations  described  in  this 
review  have  enormous  therapeutic  potential  and 
increasing  our  capacity  to  harness  their  power  to 
address  unmet  medical  needs  and  reduce  human 
suffering  is  the  holy  grail  of  current  biomedical 
research.  FGFs  could  well  be  added  to  the  toolbox 
required to achieve this goal. 
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